Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments

dc.contributor.authorSánchez, Aroha B.
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorMallandrich Miret, Mireia
dc.contributor.authorClares Naveros, Beatriz
dc.date.accessioned2021-02-11T10:44:16Z
dc.date.available2021-02-11T10:44:16Z
dc.date.issued2019-11-29
dc.date.updated2021-02-11T10:44:16Z
dc.description.abstractThe absorption study of drugs through different biological membranes constitutes an essential step in the development of new pharmaceutical dosage forms. Concerning orally administered forms, methods based on monolayer cell culture of Caco-2 (Caucasian colon adenocarcinoma) have been developed to emulate intestinal mucosa in permeability studies. Although it is widely accepted, it has disadvantages, such as high costs or high technical complexity, and limitations related to the simplified structure of the monolayer or the class of molecules that can be permeated according to the transport mechanisms. The aim of this work was to develop a new ex vivo methodology which allows the evaluation of the intestinal apparent permeability coefficient (Papp) while using fewer resources and to assess the correlation with Caco-2. To this end, pig (Sus scrofa) duodenum segments were mounted in Franz diffusion cells and used to permeate four different drugs: ketorolac tromethamine (Kt), melatonin (Mel), hydrochlorothiazide (Htz), and furosemide (Fur). No statistically significant differences (p > 0.05) were observed corelating Papp values from Franz diffusion cells and Caco-2 cell experiments for Kt, Htz, and Fur. However, there were statistically significant differences (p < 0.05) correlating Papp values and Mel. The difference is explained by the role of Mel in the duodenal epithelial paracellular permeability reduction. Ex vivo permeation may be an equivalent method to Caco-2 for drugs that do not produce intestinal membrane phenomena that could affect absorption.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec694715
dc.identifier.issn1999-4923
dc.identifier.pmid31795506
dc.identifier.urihttps://hdl.handle.net/2445/173874
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11120638
dc.relation.ispartofPharmaceutics, 2019, vol. 11, num. 12, p. 638
dc.relation.urihttps://doi.org/10.3390/pharmaceutics11120638
dc.rightscc-by (c) Sánchez, Aroha B. et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationMedicació transdèrmica
dc.subject.classificationMucosa gastrointestinal
dc.subject.classificationDisseny de medicaments
dc.subject.otherTransdermal medication
dc.subject.otherGastrointestinal mucosa
dc.subject.otherDrug design
dc.titleValidation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
694715.pdf
Mida:
3.7 MB
Format:
Adobe Portable Document Format